Overview
Compare with Geron Corporation, Design Therapeutics, Inc. or CytoMed Therapeutics Ltd, or pick any stock.
- TickerRGBP on OTC2
- IndustryPharmaceutical Preparations2
- HeadquartersLa Mesa, United States2
- Incorporated inNV5
- Business address4700 Spring St #304, La Mesa, Ca 919425
- Filer categoryNon-accelerated filer, Smaller reporting company5
- Legal formProfit Corporation2
- LEI549300S6GNPDQ0F5FT792
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O Resident Agents of Nevada, Inc., 89701 Carson City, United States2
See how the biggest companies compare on our leaderboards
No clinical trials on our product candidates have commenced so no conclusions of efficacy can be made.6 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development5¢$11.7K
- Other costs95¢$224.8K
Out of $236.6K in revenue.34 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-09-30 | 2024-09-30 |
|---|---|---|
| Net revenue | $236.6K | $236.6K |
| Research and Development | $11.7K | $153.7K |
| General and Administrative | $75.1K | $58.9K |
| Consulting and Professional Fees | $398.3K | $364.0K |
| Rent | $90.0K | $77.2K |
| Total operating expenses | $575.1K | $653.8K |
| Loss from operations | -$338.5K | -$417.2K |
| Interest Expense | -$158.3K | -$72.4K |
| Interest Expense attributable to Amortization of Discount | -$52.1K | -$29.0K |
| Derivative Income (Expense) | -$675.5K | -$4.1K |
| Penalties | -$50.0K | $0 |
| Financing Fees | -$145.5K | |
| Total other income (expense), net | -$936.0K | -$251.0K |
| Net loss before income taxes | -$1.3M | -$668.3K |
| Income tax provision | $0 | $0 |
| Net loss | -$1.3M | -$668.3K |
| Net loss per common share, basic | -$0.05 | -$0.16 |
| Net loss per common share, diluted | -$0.05 | -$0.16 |
| Number of weighted average shares - basic | 23.5M shares | 4.1M shares |
| Number of weighted average shares - diluted | 23.5M shares | 4.1M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.3
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Cash | $69.6K | $716 | ||
| Accounts receivable, related party | $204.9K | $94.9K | ||
| Prepaid expenses | $200 | $47.8K | ||
| Total Current Assets | $274.6K | $143.4K | ||
| TOTAL ASSETS | $274.6K | $161.1K | ||
| Accounts payable | $1.7K | $29.7K | ||
| Accrued expenses | $1.8M | $1.7M | ||
| Unearned income | $1.3M | $1.5M | ||
| Derivative liability | $2.1M | $1.4M | ||
| Convertible notes payable, net of unamortized debt discount | $1.0M | $499.9K | ||
| Other current liabilities | $99.8K | $21.0K | ||
| Total Current Liabilities | $6.6M | $5.4M | ||
| TOTAL LIABILITIES | $6.6M | $5.4M | ||
| Common Stock ($.0001 par value) 5,800,000,000 authorized and 39,374,704 and 5,258,235 shares issued and outstanding, respectively | $3.9K | $527 | ||
| Additional Paid in capital | $15.6M | $15.4M | ||
| Other Comprehensive Income | -$222.6K | -$204.8K | ||
| Retained Earnings (Deficit) | -$21.7M | -$20.4M | ||
| Total Stockholders Equity (Deficit) | -$6.3M | -$5.2M | -$5.1M | |
| TOTAL LIABILITIES & STOCKHOLDERS EQUITY (DEFICIT) | $274.6K | $161.1K | ||
| Common stock, par value | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock, shares authorized | 5.8B shares | 5.8B shares | 5.8B shares | 500.0M shares |
| Common stock, shares issued | 39.4M shares | 5.3M shares | 3.5M shares | 3.4M shares |
| Common stock, shares outstanding | 39.4M shares | 5.3M shares | 3.5M shares | 3.4M shares |
| Preferred stock, par value | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred stock, shares authorized | 800.0M shares | 800.0M shares | 800.0M shares | 800.0M shares |
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Cash | $69.6K | $716 | ||
| Accounts receivable, related party | $204.9K | $94.9K | ||
| Prepaid expenses | $200 | $47.8K | ||
| Total Current Assets | $274.6K | $143.4K | ||
| TOTAL ASSETS | $274.6K | $161.1K | ||
| Accounts payable | $1.7K | $29.7K | ||
| Accrued expenses | $1.8M | $1.7M | ||
| Unearned income | $1.3M | $1.5M | ||
| Derivative liability | $2.1M | $1.4M | ||
| Convertible notes payable, net of unamortized debt discount | $1.0M | $499.9K | ||
| Other current liabilities | $99.8K | $21.0K | ||
| Total Current Liabilities | $6.6M | $5.4M | ||
| TOTAL LIABILITIES | $6.6M | $5.4M | ||
| Common Stock ($.0001 par value) 5,800,000,000 authorized and 39,374,704 and 5,258,235 shares issued and outstanding, respectively | $3.9K | $527 | ||
| Additional Paid in capital | $15.6M | $15.4M | ||
| Other Comprehensive Income | -$222.6K | -$204.8K | ||
| Retained Earnings (Deficit) | -$21.7M | -$20.4M | ||
| Total Stockholders Equity (Deficit) | -$6.3M | -$5.2M | -$5.1M | |
| TOTAL LIABILITIES & STOCKHOLDERS EQUITY (DEFICIT) | $274.6K | $161.1K | ||
| Common stock, par value | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock, shares authorized | 5.8B shares | 5.8B shares | 5.8B shares | 500.0M shares |
| Common stock, shares issued | 39.4M shares | 5.3M shares | 3.5M shares | 3.4M shares |
| Common stock, shares outstanding | 39.4M shares | 5.3M shares | 3.5M shares | 3.4M shares |
| Preferred stock, par value | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred stock, shares authorized | 800.0M shares | 800.0M shares | 800.0M shares | 800.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-09-30 | 2024-09-30 |
|---|---|---|
| Net Income (loss) | -$1.3M | -$668.3K |
| Changes in derivative liability | $675.5K | $4.1K |
| Increase (Decrease) in Interest expense attributable to amortization of Discount | $52.1K | -$29.0K |
| Preferred Stock issued for Compensation | $13.0K | |
| Common Stock issued for Compensation | $37.5K | |
| Common Stock issued for Expenses | $128.1K | $145.5K |
| (Increase) Decrease in Accounts Receivable | -$110.0K | -$94.9K |
| (Increase) Decrease in Prepaid Expenses | $47.6K | -$37.8K |
| Increase (Decrease) in Accounts Payable | $821 | -$7 |
| Increase (Decrease) in Accrued Expenses | $173.3K | $19.9K |
| Increase (Decrease) in Penalties | $50.0K | $0 |
| Increase (Decrease) in Unearned Income | -$126.6K | -$141.7K |
| Net Cash Provided by (Used in) Operating Activities | -$383.6K | -$751.5K |
| Increase (Decrease) in Convertible Notes Payable | $194.6K | -$10.0K |
| Increase (Decrease) in Notes Payable | $77.5K | |
| Increase (Decrease) Other Liabilities | $50.0K | |
| Common stock issued for cash | $58.2K | $563.7K |
| Borrowings from notes payable to related parties | $149.6K | |
| Net Cash Provided by (Used in) Financing Activities | $452.4K | $631.2K |
| Net Increase (Decrease) in Cash | $68.8K | -$120.3K |
| Common Shares issued for Notes Payable | $42.1K | $0 |
| Convesion of Notes Payble to Convertible Debt | $232.1K | $0 |
| Common Shares issued for interest | $44.4K | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
Regen BioPharma Inc sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Regen BioPharma Inc
- Quick Capital, LLC Filed SCHEDULE 13G on Regen BioPharma Inc, latest Sep 12, 2025
- Regen BioPharma Inc La Mesa, California, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Regen BioPharma Inc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $69.6K3 Sep 30, 2025 | $7163 Sep 30, 2024 | +9614.4% |
Properties, in its own words
The Company currently occupies 1,000 square feet of office space provided by the Company’s Chief Executive Officer free of charge on a month to month basis. The property is utilized as office space. We believe that the foregoing properties are adequate to meet our current needs for office space.
Item 2 of the 10-K filed Dec 30, 2025.6
Timeline
- Jul 15, 20268-K Entered a material agreement; Change of auditor; Other events15
- Mar 4, 20268-K Unregistered sale of shares16
- Feb 2, 20268-K Unregistered sale of shares17
- Jan 21, 20268-K Other events18
- Nov 13, 20258-K Unregistered sale of shares19
- Oct 3, 20258-K Entered a material agreement; Unregistered sale of shares; Other events20
- Sep 19, 20258-K Unregistered sale of shares21
- Aug 7, 20258-K Entered a material agreement; Unregistered sale of shares22
- Aug 1, 20258-K Entered a material agreement; Unregistered sale of shares23
- Jun 11, 20258-K Unregistered sale of shares24
- May 13, 20258-K Earlier financial statements no longer reliable25
- Apr 7, 20258-K Change of auditor26
Calendar
When it reported results
- Nov 29, 2024Reported quarterly or annual results27
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
109 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 40 major events, 1 large holders, 47 other. The latest 20:
- Aug 17, 202610-Q EDGAR
- Aug 13, 2026NT 10-Q EDGAR
- Jul 15, 20268-K EDGAR
- May 14, 202610-Q EDGAR
- Mar 4, 20268-K EDGAR
- Feb 13, 202610-Q EDGAR
- Feb 2, 20268-K EDGAR
- Jan 21, 20268-K EDGAR
- Jan 12, 2026QUALIF EDGAR
- Jan 8, 20261-A POS EDGAR
- Dec 30, 202510-K EDGAR
- Dec 5, 2025253G1 EDGAR
- Dec 3, 2025QUALIF EDGAR
- Dec 1, 2025CORRESP EDGAR
- Nov 17, 20251-A EDGAR
- Nov 13, 20258-K EDGAR
- Oct 3, 20258-K EDGAR
- Sep 19, 20258-K EDGAR
- Sep 12, 2025SCHEDULE 13G EDGAR
- Sep 8, 2025253G1 EDGAR
The 109 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Quick Capital, LLCSCHEDULE 13G, 1 filing Sep 12, 202528
SEC filer profile
How Regen BioPharma Inc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARRegen BioPharma Inc1
- CIK0001589150
- Employer ID (EIN)45-51929976
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company6
- Incorporated inNevada6
- Fiscal year endsSeptember 301
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address4700 Spring St #304, La Mesa, CA 919421
- Phone619-722-55051
- Shares outstanding1,675,277,503 as of Aug 12, 20264
- Public float$1.1M as of Mar 31, 20256
- AuditorBCRG Group, Irvine, CA PCAOB ID 7158; it also attests to the company’s internal control over financial reporting6
- On EDGAR sinceOct 15, 20131
- Filings262 in all: 8-K (117), 10-Q (38), CORRESP (14), 10-Q/A (13), 10-K (12), 424B3 (11), UPLOAD (9), 10-K/A (5)1
All 27 form types
8-K/A (5), S-1/A (5), QUALIF (4), 1-A (3), 253G1 (3), EFFECT (3), S-1 (3), 1-A POS (2), 1-A/A (2), 15-15D/A (2), NT 10-K (2), NT 10-Q (2), 1-A-W (1), 15-15D (1), NT 10-Q/A (1), RW (1), S-8 (1), SC 13G (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (10-K) Dec 30, 2025
Quarterly report (10-Q) Aug 17, 2026
Latest 8-K (8-K) Jul 15, 2026
Risk factors and legal proceedings
Legal proceedings
There are no material pending legal proceedings to which the Company is a party or of which any of the Company’s property is the subject.
The opening of Item 3, Legal Proceedings.6
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARUnregistered sale of shares
- 17SEC EDGARUnregistered sale of shares
- 18SEC EDGAROther events
- 19SEC EDGARUnregistered sale of shares
- 20
- 21SEC EDGARUnregistered sale of shares
- 22
- 23
- 24SEC EDGARUnregistered sale of shares
- 25
- 26SEC EDGARChange of auditor
- 27
- 28